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Abstract
Switched systems in which the manipulated control action is the time-depending
switching signal describe many engineering problems, mainly related to biomedical
applications. In such a context, to control the system means to select an autonomous
system - at each time step - among a given finite family. Even when this selection
can be done by solving a Dynamic Programming (DP) problem, such a solution is
often difficult to apply, and state/control constraints cannot be explicitly considered.
In this work a new set-based Model Predictive Control (MPC) strategy is proposed to
handle switched systems in a tractable form. The optimization problem at the core of
the MPC formulation consists in an easy-to-solve mixed-integer optimization problem,
whose solution is applied in a receding horizon way. Two biomedical applications are
simulated to test the controller: (i) the drug schedule to attenuate the effect of viral
mutation and drugs resistance on the viral load, and (ii) the drug schedule for Triple
Negative breast cancer treatment. The numerical results suggest that the proposed strat-
egy outperform the schedule for available treatments.
Keywords: Model Predictive Control, Switched Systems, Stability, Biomedical
Treatment, Resistance.
1. Introduction
Many engineering problems related to the control of mechanical, automotive,
power, aircrafts, traffic, and biomedical dynamical systems can be properly described
by the so-called switched systems. Switched systems are dynamical systems consisting
in a collection of subsystem and a rule (switching signal) that governs the switching
among them. The dynamical subsystems of the collection can be autonomous (un-
controlled) or controlled, while the switching signal can be state-dependent or time-
dependent [1]. In this work the interest is put on the autonomous, time-dependent case.
In this context, the switching signal may be regarded as the manipulated control action
(the decision variable), in such a way that the control objective is achieved (exclusively)
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by a proper combination of subsystems trough the time. A particularly interesting ap-
plication of such kind of switched systems is the problem of scheduling therapies in
different biomedical problems [2, 3]. In [3], for instance, the control problem of min-
imizing the viral load while delaying the emergence of highly resistant mutant viruses
[4] is studied, by means of a switching strategy. Each autonomous submodel represents
the virus dynamic under a given specific treatment (specified by a given drug or com-
bination of drugs), and the switching signal decides which treatment is used at each
time. The clinical goal is to delay the time until patients exhibit resistant strains to
all existing drug regimens [5]. One of the challenging problem is the crucial trade-off
between switching therapies: on the one hand, switching early carries the risk of poor
adherence to a new drug regimen and prematurely exhausting the limited number of
remaining therapies; on the other hand, switching drugs too late allows the accumula-
tion of mutations that leads to multi-drug resistance [6]. In [2] a switched linear system
of the response of the Triple Negative breast cancer cell line to different treatment is
studied. A cyclic drug schedule is proposed based on the hypotheses that some drugs
can shrink the live cancer cell population, but they are very toxic to healthy cells [7]
(transient rather than long-term efficacy, low rate of response, negative secondary re-
actions [8, 9, 10]). On the other hand, other drugs only slow down the growth of the
live cancer cell population, but are less toxic to healthy cells.
Concerning the techniques able to solve the previous problem, Dynamic Program-
ming, (DP) [11] is a first strategy suitable to compute the optimal sequence of subsys-
tem, for a given switched system problem. However, the DP solution is often difficult
to apply (impossible in most of the cases), and state/control constraints cannot be ex-
plicitly considered. One step ahead is the Model Predictive Control (MPC) strategy,
which by means of the Receding Horizon Control (RHC) policy overcomes all the im-
plementation problems of DP, as stated in [12]. The main features of MPC - which
make it one of the most employed advanced control technique - are the explicit consid-
eration of a model for prediction, the optimal computation of the control actions, and its
ability to handle, easily and effectively, hard constraints on control and states [13, 12].
MPC theoretical background has been widely investigated in the last decades, showing
how this technique is capable to provide stability, robustness, constraint satisfaction
and tractable computation for linear and nonlinear systems [14, 15]. Set invariance
theory, which is closely related to Lyapunov stability theory [16], has also shown to
be a powerful tool for analyzing dynamical systems subject to constraints. Set-based
MPC [17] seems to be an appropriate strategy to undertake such a control problems.
The application of the MPC to switched systems is a growing field; the switch-
ing law is in fact either considered as a perturbation [18] or as part of the control
inputs. In this last case, conditions for stabilizability have been provided by using a
min-switching policy [1], and Lyapunov–Metzler inequalities [19]. In this context, the
stability of switched systems is neither intuitive nor trivial: switching between indi-
vidually stable sub-systems may cause instability and conversely, switching between
unstable sub-systems may yield a stable switched system [1]. The easy implementation
and the anticipatory nature of the MPC seems an appropriate strategy for computing
switching laws, since it may anticipate the activation of possible switching. Moreover,
set-theory has been recently used in the context of stability of switching systems [20],
suggesting that set-basedMPC approach is a promising tool for the analysis of stability,
robustness and constraint satisfaction of this kind of systems.
This paper studies the behavior of a discrete-time switched system and a the in-
variance and controllable sets of the state space for this type of systems. A novel
set-based MPC formulation for discrete-time switched linear systems is presented with
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asymptotic stability guaranteed. The performance of the proposal is assessed by several
simulations in the biomedical fields, a viral mutation problem and a drug scheduling
synthesis for cancer treatment is addressed showing that the proposed MPC outper-
formed the available treatments.
The paper is organized as follows, Section 2 introduces the switched linear sys-
tem and an optimal control solution, Section 3 presents an invariance set-theory for
switched systems, in Section 4 the set-basedMPC is formulated and the asymptotic sta-
bility is proved, Section 5 address with several simulations the application to biomedi-
cal problems and Section 6 states the conclusion of the work.
1.1. Notation
We denote, by N the set of natural numbers, by Nq = {n ∈ N : 1 ≤ n ≤ q}, by Z
the set of integer numbers, by Z≥0 the set of non-negative integers, by Zq = {n ∈ Z :
0 ≤ n ≤ q}, and by Zl:q = {n ∈ Z : l ≤ n ≤ q}. The Euclidean distance between
two points x, y on Rn is represented by d(x, y). The distance from a point x ∈ Rn to
a set Ω is defined as dΩ(x) := inf{d(x, y) : y ∈ Ω}. We define the cardinal number
of a set Ω as | Ω |. The interior of a set Ω ⊆ Rn is denoted by intΩ. A set Ω ⊆ Rn
is called star-convex with respect to the origin if for all x ∈ Ω the line segment from 0
to x is in Ω. A set Ω ⊆ Rn is a C∗-set if it is compact, star-convex with respect to the
origin and 0 ∈ intΩ.
2. Discrete-time linear switched system and optimal control solution
Consider the discrete-time switched system described by
x(k + 1) = Aσ(k)x(k), (2.1)
with x(0) = x0, where x(k) ∈ X ⊂ R
n is the system state at the k–th sample time,
and the set X is closed. σ(k) ∈ Σ := {1, 2, . . . , q} is the switching signal that, at any
instant, selects indirectly a transition matrix Ai ∈ R
n×n for i ∈ Σ. In what follows
the signal σ(·) is considered as manipulable variable. The problem of stabilizability
consists in proving the existence of switching signals that yield asymptotic stability if
applied to (2.1).
In general, different initial conditions may correspond to different switching paths,
because a switching path σ = {σ(0), σ(1), . . . , σ(T − 1)} depends heavily on the ini-
tial state x0 [21]. This is a critical feature which makes the switched system essentially
distinct from a linear time-varying system, where all initial states correspond to a single
path (further details in [21, Example 1.5]).
Let Lσ ∈ N and Uσ ∈ N which depends on every signal σ ∈ Σ with Lσ ≤ Uσ .
The following assumption implies that every switching signal σ must be applied to the
system at least Lσ instant of times and no more than Uσ instant of times.
Assumption 2.1 (Waiting times). Every signal σ ∈ Σ must be applied to the switched
system (2.1) at least Lσ times and no more than Uσ times.
Generally, to corner the above assumption in the bibliography it is considered the
following sequence
{(σ(0), h(0)), (σ(1), h(1)), . . . , (σ(T − 1), h(T − 1))} (2.2)
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where h(j) is an optimization variable that represents the number of times that signal
σ(j) is applied to the system, for j ∈ ZT−1. With this arrangement Assumption 2.1
hold with
Lσ(j) ≤ h(j) ≤ Uσ(j)
for all j ∈ ZT−1.
In what follows, different notation will be used in such a way there is no need to
add another variable, h(j), to the optimization problem.
Consider the following definition.
Definition 2.2 (j-pack). Given a switching path σ = {σ(0), σ(1), . . . , σ(T − 1)}. For
every time j ∈ ZT−1 we define the j-pack set associated with σ by
P [σ, j] := {σ(k + j) : with k ∈ Z−j:T−1−j such that σ(j) = σ(j + i) ∀ i = 0,±1, . . . , k}.
(2.3)
The term i = 0,±1, . . . , k in (2.3) depends on the sign of k, that is
if k ≥ 0⇒ i = 0, 1, . . . , k
if k < 0⇒ i = 0,−1, . . . , k.
The set P [σ, j] is composed by all signals in σ consecutively identical to the signal
σ(j). According to Eq. (2.3),
• σ(j) ∈ P [σ, j] for all j ∈ ZT−1.
• If σ(k + j) ∈ P [σ, j] for some k ∈ Z0:T−1−j ⇒ σ(k + j) = σ(j), moreover
σ(j) = σ(j + 1) = σ(j + 2) = · · · = σ(j + k),
i.e., σ(j + 1) ∈ P [σ, j], σ(j + 2) ∈ P [σ, j], . . . , σ(j + k) ∈ P [σ, j].
• If σ(k + j) ∈ P [σ, j] for some k ∈ Z−j:0,⇒ σ(k + j) = σ(j), moreover
σ(j) = σ(j − 1) = σ(j − 2) = · · · = σ(j + k),
i.e., σ(j − 1) ∈ P [σ, j], σ(j − 2) ∈ P [σ, j], . . . , σ(j + k) ∈ P [σ, j].
• For instance, ifσ = {1, 2, 2, 2, 3, 3, 2}, thenP [σ, 0] = {1},P [σ, 1] = {2, 2, 2},
P [σ, 2] = {2, 2, 2}, P [σ, 3] = {2, 2, 2}, P [σ, 4] = {3, 3}, P [σ, 5] = {3, 3},
P [σ, 6] = {2}.
This way, variable h(j) from Eq.(2.2) is not necessary to address Assumption 2.1.
Instead the following property will be considered,
Property 2.3. A switching path σ = {σ(0), σ(1), . . . , σ(T − 1)} fulfills Assump-
tion 2.1 if
Lσ(j) ≤| P [σ, j] |≤ Uσ(j)
for all j ∈ Z0:T−1.
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2.1. Optimal solution for discrete-time positive switched system
In this section we introduce the optimal control for the discrete-time positive
switched system (2.1). In order to stabilize the origin, we consider the cost function
JN (x,σ) =
N−1∑
k=0
cσ(k)x(k) + cx(N) (2.4)
where x = x(0) is the current state; x(j + 1) = Aσ(j)x(j), for j ∈ ZN−1; σ is a
switching discrete path, cσ(j) is a positive weight vector corresponding to signal σ(j),
and vector c is a positive final weight. Cost function (2.4) must satisfy the Hamil-
ton–Jacobi–Bellman equation [22].
If we define the optimal switching signal, the corresponding trajectory and the
optimal cost functional as σ0(k), x0(k) and JN (x,σ
0), respectively, where σ0 :=
{σ0(0), . . . , σ0(N − 1)}. Using the Hamilton–Jacobi–Bellman equation for the dis-
crete case, we have:
V(x(k), k) = min
σ(k)∈Σ
{cσ(k) + V(x(k + 1), k + 1)}.
The general solution for this system is given by
V(x(k), k) = p(k)′x(k),
where p(k) denote the costate vector. Therefore, the following nonlinear system is
obtained:
x0(k + 1) = Aσ0(k)x
0(k), x(0) = x0 (2.5)
p0(k) = A′σ0(k)p
0(k + 1) + cσ0(k), p(T ) = c
σ0(k) = arg min
s
{p0(k + 1)′Asx
0(k) + csx
0(k).}
The state equation is subject to an initial condition and is solved forwards in time,
whereas the costate equation must be integrated backward, both according to the cou-
pling condition given by the switching rule. As a result, the problem is a two-point
boundary value problem, and cannot be solved using regular iteration techniques.
However, as detailed in [23], obtaining the aforementioned solution could be diffi-
cult, if not impossible, because of the computational complexity. In the next section,
a Receding Horizon (RHC) strategy will be presented that - although sub-optimal -
reasonably approximates the optimal solution, at a significant smaller computational
cost. Furthermore, the proposed strategy allows to consider a complete cost function
(penalizing the states all along a given horizon) and considers full state constraints.
3. Invariance for switched systems
The set-theory is an important tool for the analysis of dynamic systems. In particu-
lar, there is no consensus for the characterization of invariant sets for switched systems.
In what follows, we present an analysis of invariance for switched systems that follows
the general concept of classical invariance from [16]. Additionally, sufficient condi-
tions for its existence is presented.
Definition 3.1 (Switched invariant set). A set Ω ⊂ X is a switched invariant set (SIS)
of system (2.1) if for all x ∈ Ω, there exists σ ∈ Σ such that Aσx ∈ Ω.
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Figure 1: A switched invariant set, Ω, according to Proposition 3.4. Figure shows that Ω ⊂ S(Ω,Σ).
In this section we suppose the following assumption.
Assumption 3.2. The matrices Ai, with i ∈ Σ are nonsingular.
Definition 3.3 (Controllable set). Given a set Ω ⊂ X , the controllable set to Ω,
S(Ω,Σ), is defined by
S(Ω,Σ) :=
⋃
i∈Σ
A−1i Ω. (3.1)
As usual, the characterization of the invariance can be done with the analysis of the
controllable set, i.e. a set is an invariant set if and only if it is contained in its control-
lable set [16]. In the context of switched systems we have the equivalent proposition:
Proposition 3.4. Let the compact and convex set Ω ⊂ X such that Ω ⊆ S(Ω,Σ), then
Ω is a SIS of system (2.1).
Proof. Let x ∈ Ω, then by equation (3.1), there exists i ∈ Σ such that x ∈ A−1i Ω.
ThereforeAix ∈ Ω.
Figure 1 shows a set Ω, such that Ω ⊆
⋃
i∈ΣA
−1
i Ω but Ω 6⊆ A
−1
i Ω for any i =
1, 2, 3, meaning thatΩ is an invariant set for the switched system x(k+1) = Aσ(k)x(k)
with σ(k) ∈ Σ = {1, 2, 3}, but is not an invariant set for neither of the autonomous
linear sub-systems x(k + 1) = Aix(k) for i = 1, 2, 3. This points to the fact that a
switched system can be stable even if it is composed by unstable sub-systems [1].
Definition 3.5 (i-Step controllable set). Given a set Ω ⊂ X , the i-step controllable set
to Ω, Si(Ω,Σ), is defined by the following algorithm:
i. Initialization: S1(Ω,Σ) := S(Ω,Σ).
ii. Iteration: Si(Ω,Σ) := S(Si−1(Ω,Σ),Σ).
Proposition 3.6. ([20, Algorithm 1]) Let Ω ⊆ Rn be a C∗-set, if there exists k ∈ Z≥0
such that
Ω ⊆ int
⋃
j∈Nk+1
Sj(Ω,Σ),
then there is a switching law stabilizing the switched system (2.1).
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Proposition 3.7. ([20, Algorithm 3]) Let Ω ⊆ Rn be a C∗-set, and define the set
Ωˆk+1 :=
⋃
j∈Nk+1
Sj(Ω,Σ) ∪ Ω,
if there exists k ∈ Z≥0 such that
Sk+1(Ω,Σ) ⊆ Ωˆk,
then there is no switching law stabilizing the switched system (2.1).
4. Switching set-based MPC (SwMPC)
This section introduces a proper set-based MPC for switched systems with
guaranteed asymptotic stability of the closed-loop system.
For a given (fixed) horizon N ∈ N, and a target set Ω ⊆ X , compact, convex and
with the origin in its interior, the following (set-dependent) cost function is proposed:
JN (x;σ) :=
N−1∑
j=0
cσ(j)dΩ(x(j)) + cdΩ(x(N)) (4.1)
where x = x(0) is the current state; x(j + 1) = Aσ(j)x(j), for j ∈ ZN−1; σ is a
switching discrete path, cσ(j) is a positive weight vector corresponding to signal σ(j),
and vector c is a positive final weight.
Let us consider a binary variable αji ∈ {0, 1}, for all i ∈ Σ and j ∈ ZN−1, such
that:
• αji = 1⇒ σ(j) = i
• αji = 0⇒ σ(j) 6= i.
Then, if we consider the set of integer optimization variables α = {αji , i ∈ Σ, j ∈
ZN−1}, the sequence of signals σ can be obtained by the matrix α.
Consider a target set Ω ∈ X , and the initial state x at time k. The optimization
problem is defined as follow:
min
α
JN (x;σ(α)) (4.2)
s.t. x(0) = x, (4.3)
x(j + 1) =
q∑
i=1
αjiAσ(j)x(j), j ∈ ZN−1, (4.4)
αji ∈ {0, 1}, j ∈ ZN−1, i ∈ Σ, (4.5)
q∑
i=1
αji = 1, j ∈ ZN−1, (4.6)
x(j) ∈ X , j ∈ ZN−1 (4.7)
σ(j) = {i : αji = 1}, j ∈ ZN−1 (4.8)
x(N) ∈ Ω. (4.9)
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Eq. (4.3) is the initialization of the problem. Eq. 4.4 the evolution of the switched
system in terms of the variable αji . Eq. 4.5 the integer optimization variables. Eq. 4.6
means that only one signal is applied in every step j. Eq. 4.8 relates signal σ(j) with
the optimization variable αji , and Eq. 4.9 is the final constraint which implies that the
final predicted state belongs to the target set Ω.
Problem (4.2) does not necessarily meet the waiting time of Assumption 2.1. To
fulfill Assumption 2.1 we use Property 2.3. First, let us state that
U = max
σ∈Σ
{Uσ}.
We define a memory switching path σm by
σm := {σ
0(−U), σ0(−U + 1), . . . , σ0(−1)︸ ︷︷ ︸
memory
, σ(0), σ(1), . . . , σ(N − 1)︸ ︷︷ ︸
predictions
},
where the first U elements of σm are the last U optimal solutions applied to the real
system, and the lastN−1 elements of σm are theN predictions (or decision variables)
of Problem (4.2).
Remark 4.1 (Waiting time constraint). For the closed-loop system satisfies Assump-
tion 2.1 the following constraint should be added to the restrictions of Problem (4.2):
Lσ(j) ≤| P [σm, j] |≤ Uσ(j), j ∈ Z0:N−1. (4.10)
Note that the j-pack P [σm, j] -that accounts for all switching signals consecutively
identical to the prediction signal σ(j)- must depend on the past optimal solutions that
already enters the closed-loop system, that is the reason to consider the j-pack of σm.
The control law, derived from the application of a receding horizon control policy
is given by κMPC(x) = σ
0(0), where σ0(0) is the first element of the solution se-
quence σ0 of Problem (4.2). Therefore, the closed-loop system under the MPC law is
described by
x(k + 1) = AκMPC(x(k))x(k), (4.11)
and the optimal cost function is given by
J0N (x) = JN (x,σ
0(x)). (4.12)
The domain of attraction of Problem (4.2), i.e. every state that can be feasible
controlled by the SwMPC, is given by SN (Ω,Σ).
Remark 4.2. The existence of a SIS implies that the domain of attraction of Prob-
lem 4.2, SN (Ω,Σ), is not empty, since Ω ⊆ SN (Ω,Σ).
The control algorithm executed at any k-th time instant is the following:
The resulting optimization problem is a Mixed Integer Quadratic Program-
ming (MIQP), which can be solved by specific solvers. For the simulations of the
present work, Algorithm 1 is implemented in YALMIP, a Toolbox for Modeling
and Optimization in MATLAB [24]. The main idea of YALMIP is providing an
efficient tool for writing high-level algorithm in MATLAB [25], while relying on
external solvers for the low-level numerical solution of optimization problems. In
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Algorithm 1 Switched MPC algorithm
Require: N ∈ N, X ⊂ Rn and Ω ⊆ X
1: Read x(k)
2: Solve (4.2) subject to (4.3)-(4.9)
3: Inject σ0(0) into the system.
4: k ← k + 1
5: Go back to 1
this work we make use of the Gurobi Optimizer (Version 8.1, Academic License),
which in turn relies on a branch-and-boundalgorithm to solveMIQP problems [26, 27].
Before present the stability proof we must assume the following.
Assumption 4.3. Switched system (2.1) is stabilizable.
Theorem 4.4. Let Assumption 4.3 holds, and consider a target set, Ω ⊂ X , of
cost (4.1), be a SIS for system (2.1). Let the initial state x(i) ∈ SN (Ω,Σ), then the set
Ω is asymptotically stable for the closed-loop system (4.11).
Proof. Since Assumption 4.3 holds and the initial state at time instant i is such that
x(i) ∈ SN (Ω,Σ), there is an optimal solution of Problem (4.2), given by,
σ
0(x) := {σ00 , σ
0
1 , . . . , σ
0
N−1},
corresponding with the optimal state sequence,
x
0(x) := {x00, x
0
1, . . . , x
0
N},
such that x00 = x(i) and x
0
N ∈ Ω (by (4.3) and (4.9)). Then, the optimal cost at time i,
J0N (x(i)), is given by,
J0N (x(i)) =
N−1∑
j=0
cσjdΩ(x
0
j ) + cdΩ(x
0
N )︸ ︷︷ ︸
=0
.
Since the target set Ω is a SIS for switched system (2.1), there is a switching signal
σ¯ ∈ Σ such that x¯ = Aσ¯x
0
N ∈ Ω. Therefore, the sequence,
σ¯ = {σ01 , σ
0
2 , . . . , σ
0
N−1, σ¯},
is a feasible solution of Problem (4.2) at time i+ 1, with the feasible state sequence,
x¯ = {x01, x
0
2, . . . , x
0
N , x¯}.
This feasible solution corresponds to the following cost:
JN (x(i + 1); σ¯) =
N−1∑
j=1
cσjdΩ(xj).
Note that, by manipulating J0N (x(i)) and JN (x(i + 1); σ¯), we have the following
equation:
JN (x(i + 1); σ¯)− J
0
N (x(i)) = −cσ0dΩ(x0)
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= −cσ0dΩ(x(i)).
Therefore, the optimal cost function at time i + 1, J0N (x(i + 1)), is such that,
J0N (x(i + 1))− J
0
N (x(i)) ≤ JN (x(i + 1); σ¯)− J
0
N (x(i)) (4.13)
= −cσ0dΩ(x(i)),
Eq. (4.13) implies that the positive sequence J0N (x(k)) decrease when k →∞, thus it
is easy to prove that J0N (x(k)) → 0 when k →∞. Therefore, by Eq. (4.13),
dΩ(x(k)) → 0,
when k →∞, which means the closed-loop system converges to the desired target set
Ω.
4.1. Illustrative Example
Consider the system 2.1 with Σ = {1, 2, 3, 4}, n = 2 and
A1 =
[
1.5 0
0 −0.8
]
, A2 = 1.1R(
2π
5
).
A3 = 1.05R(
2π
5
− 1), A4 =
[
−1.2 0
1 1.3
]
.
where R(·) is the rotation matrix. This is an example of a stabilizable switched system
settled for 4 not Schur sub-systems A1, A2, A3 and A4 (see [20, Example 2]).
-0.5 -0.4 -0.3 -0.2 -0.1 0 0.1 0.2 0.3 0.4 0.5
x1
-0.5
0
0.5
x
2
SwMPC strategy
0 5 10 15 20 25 30
time
1
2
3
4
Figure 2: Optimal trajectory (top figure). Optimal switching signal sequence (down figure).
Figure 2 shows the application of the proposed SwMPC with a prediction horizon
N = 15, a target set is Ω = {~0} (particular case of SIS). The state constraint {x :
−10 ≤ x1 ≤ 10;−10 ≤ x2 ≤ 10}, and simulation time of T = 30. The initial state
x0 = [−0.5, 0.5] belongs to the N -controllable set SN (Ω,Σ).
5. Applications to biomedical problems
This section presents two particular applications of the SwMPC previously dis-
cussed.
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5.1. Drug schedules to mitigating viral escape
We focus on the problem of treatment scheduling to minimize the adverse effects
of virus mutation in acute and chronic infections. Acute infections are caused by virus
that grows out but it is cleared in a short period. On the other hand, in chronic viral
infections the virus grows slowly promoting persistence. In both scenarios, the main
problematic is given by the rise to drug resistance. For this work we focus on the virus
mutation treatment problem. For this reason we use a model for mutation dynamics
that is simple enough to allow control analysis and optimization of treatment switching
[23]. The model is given by:
V˙i(t) =ρi,σ(t)Vi(t)− δVi(t) +
∑
i6=j
µmi,jVj(t) (5.1)
where µ is a small parameter representing the mutation rate, δ is the death or decay rate
of the virus and mi,j ∈ {0, 1} represents the genetic connections between genotypes,
that is, mi,j = 1 if and only if it is possible for genotype j to mutate into genotype i.
Equation (5.1) can be rewritten as
V˙ (t) =(Rσ(t) − δI)V (t) + µMV (t) (5.2)
whereM := [mi,j ] and Rσ(t) := diag{ρi,σ(t)}, and every element of V (t) is a partic-
ular genotype.
We take a model with four genetic variants and two possible drug therapies, as
shown in Figure 3.
Figure 3: The virus V1 is susceptible to both therapies. V2 is susceptible to therapy 2 while V3 is susceptible
to therapy 1. There is a highly resistant genotype (V4) which is resistant to therapy 1 and 2.
Figure 3 shows a mutation graph that is symmetric and circular, only connections:
V1(t) ↔ V2(t), V2(t) ↔ V4(t), V4(t) ↔ V3(t), V3(t) ↔ V1(t) are possible. This
leads to the mutation matrix:
M =


0 1 1 0
1 0 0 1
1 0 0 1
0 1 1 0

 (5.3)
5.1.1. Numerical results
This section provided some simulations results to schedule the treatment for viral
mutation problems. First, we will define therapeutic strategies that are recommended
in clinics:
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Scenario V1 V2 V3 V4
1 ρ1,1 = 0.05 ρ2,1 = 0.28 ρ3,1 = 0.01 ρ4,1 = 0.27
ρ1,2 = 0.05 ρ2,2 = 0.20 ρ3,2 = 0.25 ρ4,2 = 0.27
2 ρ1,1 = 0.05 ρ2,1 = 0.40 ρ3,1 = 0.05 ρ4,1 = 0.23
ρ1,2 = 0.05 ρ2,2 = 0.05 ρ3,2 = 0.40 ρ4,2 = 0.23
Table 1: Replication rates (Rσ) for viral variants and therapy combinations. Scenarios 1 and 2 represent
chronic and acute infections respectively.
i. The switching on virologic failure (VF) strategy, recommended by [28], in-
troduce a new regimen when there is detectable viremia (Virus RNA >
1000 copies/ml) and a drug-resistant genotype is identified.
ii. The SWATCH approach, recommended by [5], is based on the possibility of
preempt virologic rebound; this strategy reduces the accumulating drug-resistant
genotypes by alternating between the two regimes every three months while viral
load is suppressed.
System (5.2) is described in discrete-time with a regular treatment interval τ =
28 days; during this time interval the treatment is considered to be fixed. If k ∈
N denotes the number of intervals, equation (5.2) can be described by the following
discrete-time switched linear system (2.1), where x(k) = x(kτ) is the sampled state
and Aσ = e
(Rσ−δI+µM)τ . The state is constrained to x(k) ∈ X := R≥0, and σ(k) ∈
{1, 2} for all k ∈ Z≥0.
Viral mutation rates are about µ = 10−4 and the connection matrix by (5.3). We
consider the initial condition
V1(0) = 1000 copies/ml, V2(0) = µV1(0),
V3(0) = µV1(0), V4(0)) = µV2(0) + µV3(0), (5.4)
and the viral clearance rate is δ = 0.24/day, which corresponds to a half life less than
3 days. As we mentioned before, the decision time is τ = 28 days, for a period of
T = 336 days.
The rates of the viral replication under treatment σ, Rσ, can define several cases,
among them the chronic and the acute infection scenarios. In [3, Chapter 7] several
chronic scenarios for replication rates are presented; some ideal cases describe a com-
plete symmetry between genotypes V2 and V3: therapy 1 inhibits V3 with the same
intensity as therapy 2 inhibits V2. More detailed models also include asymmetry in the
genetic tree with more complex structure than a simple cycle. Another scenarios show
an asymmetry for replication rates in genotypes V2 and V3, although both therapies
induce the same replication in genotypes V1 and V4 (Scenario 1, Table 1). Another
scenarios are more realistic, each genotype experience different dynamics to a new
treatment. However, all these scenarios represent chronic infections. In this work we
proposed a new one corresponding to an acute infection (e.g. influenza), characterized
by a rapid development of the viral load, which however may be cleared in short time
(Scenario 2, Table 1).
The total viral load at time instant k, Vtotal(k), is defined by Vtotal(k) =∑4
i=1 Vi(k), where Vi(k) is the viral load of genotype or strain i at time instant k.
The therapeutic strategies that we are going to test are the switching on virologic
failure (VF) and the SWATCH approach, both presented above. On the other hand,
for the presented scenarios the optimal solution will be computed by the “brute force”
12
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Figure 4: Total viral load for chronic and acute scenarios under the SwMPC strategy.
approach, which analyzes the best numerical solution of all possible combinations for
therapies 1 and 2 with decision time τ = 28 days for a period of T = 336 days. That
is, 2T/τ possible treatment combinations are evaluated and the sequence of treatments
that gives the least amount of total viral load over the whole period of time is chosen
(i.e., the one that minimizes the cost (2.4)). Notice that this approach has more com-
putational complexity as the period of time is incremented or the treatment interval is
reduced, making it a not implementable optimization.
Simulations for the switching on virologic failure show that initially the total vi-
ral load drops rapidly for the chronic infection. However, the appearance of resistant
genotype will drive a virologic failure after 200 days making a new therapy neces-
sary. The acute infection has a very different behavior; unlike the others cases, the
system can be stabilized, i.e. the total viral load can be driven to undetectable lev-
els (Vtotal(T ) ≤ 50 copies/ml). However, since the therapy changes regimen by an
exceeding of an upper bound, the total viral load does not reach its minimum values
and shows an oscillating behavior. The SWATCH strategy shows - as previously high-
lighted by [23] - a better performance than the switching on virologic failure: a lower
concentration in the total viral load over the year for chronic infections, while the viral
population is cleared in acute infection. The optimal solution for the chronic infections
is given by “brute force” approach, in order to compare performance of the proposal
with the best possible result. In the chronic infection scenario there is always a viral
escape, because the high resistance genotype rises with resistance for the two regimens.
5.1.2. MPC-based scheduling method
The same scenarios studied above will be tackled by the MPC proposed in this
work. A prediction horizon of N = 5 is considered - equivalent to 5τ days - with the
decision time τ = 28 days for a period of T = 336 days. The objective of the con-
troller is to drive the total viral load to undetectable levels (Vtotal(T ) < 50 copies/ml).
Since the objective can not be maintained over time for chronic infections due to the
promoting persistence of high resistance genotypes it is expected that the proposed
strategy delays the viral escape time. Figure 4 shows the two scenarios under the pro-
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posed SwMPC. As it can be seen, the controller suppresses the viral load, for both
cases. In the chronic infection scenario the total viral load is maintained below the
virologic failure levels, while in acute infections it is completely cleared. Figure 5, on
the other hand, shows the behavior of all genotypes only for Scenario 2, together with
the switching sequence provided by the SwMPC. The sequence is not intuitive at all,
since therapy 1 is used only three times throughout the year of treatment, in the third,
sixth and eleventh month.
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Figure 5: Viral load for Scenario 2 and treatment by the SwMPC.
Remark 5.1. It is important to highlight that in chronic infection scenarios, where
the system cannot be stabilized, the viral escape cannot be avoided. However, the
simulation results suggest that the proposed MPC delays the escape time, which is
considerably beneficial in this context.
In chronic infections the virus grows slowly, promoting this way persistence and
producing an unavoidable viral escape. This fact makes the switched system that mod-
els the infection dynamic essentially non stabilizable and, so, it will not be possible to
drive the system to the undetectable virus zone and keep it there indefinitely. So, the
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following index is proposed to compare the existing strategies with the proposal:
IT =
T∑
k=0
Vtotal(k), (5.5)
where Vtotal(k) is the total viral load at time instant k
The best performance is obtained by the optimal solution computed by “brute
force” approach, according to Table 2.
Scenario SWATCH VF OPTIMAL SwMPC
1 1587.1 5277.9 1108.4 1123.3
2 1175.6 12075.0 1067.4 1067.6
Table 2: Performance index IT for all strategies.
The indexes in Table 2 reveal that the proactive switching strategies may outper-
form the “switched on virologic failure” strategy, as it was previously stated in [23].
Nevertheless, the proposed SwMPC provides better results than SWATCH treatment,
and exhibits almost the same performance than the optimal solution, in all cases, which
is a result to be highlighted considering that the MPC is an implementable strategy,
which is robust to model-plant mismatches, explicitly considers constraints and has a
low computational burden.
In the next section we seek to address a controller synthesis problem for cancer
treatment.
5.2. Drug schedules for cancer treatment
Cancer cells have the potential to develops resistance to therapies. This is a
complex phenomenon influence by multifaceted mechanisms. Mathematical models
are important tools to further understand cancer cell dynamics and the respective
outcomes during therapies [29]. In particular model the Triple Negative breast
cancer cell line, HCC1143, with response to different drugs was obtained by a linear
time-invariant system identified in [30] and [7]. The analysis of drug schedules in
terms of switched systems was previously study in [2], with the assumptions that the
response to a drug applied at time k does not depend on the drugs applied previously
and there are some drugs that can shrink the live cancer cell population, but are very
toxic to healthy cells, and other drugs that only slow the growth of the live cancer cell
population, but are less toxic to healthy cells.
Cancer cell population can be partitioned into a finite number of observable traits
that arises from the synthesis of proteins that has important implications for drug re-
sponse, called phenotypic states; e.g., see [31]. The model of drug-treated cancer cell
population is given by the switched system (2.1), with x(k) ∈ Rn+, the non-negative
cell type vector, the elements of the sate x(k) are the number of live cells in the phe-
notypic state i = 1, 2, . . . , n, the switched signal σ belongs to a set of drugs Σ, and the
matrix, Aσ , takes the form,
Aσ =


α1 ρ21 . . . ρn1
ρ12 α2 . . . ρn2
...
...
. . .
...
ρ1n ρ2n . . . αn

 , (5.6)
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where αi := ρi−ρiD−
∑n
s=1,s6=i ρis; for all i = 1, . . . , n. The parameters ρi = ρi(σ),
ρiD = ρiD(σ), and ρij = ρij(σ) are defined in Table 3 (see [2]).
Symbol Name Definition
ρi = ρi(σ) Division pa-
rameter
Average ratio of the number of live cells in
phenotypic state i at time k + 1, derived from
their own kind, to the number of live cells in
phenotypic state i at time k
ρiD = ρiD(σ) Death gain Average proportion of live cells in phenotypic
state i at time k that begin to die, or are dead,
by time k + 1
ρij = ρij(σ) Transition gain Average proportion of live cells in phenotypic
state i at time k that transition to phenotypic
state j by time k + 1; i 6= j
Table 3: Dynamics parameters for drug σ (taken from [2]).
Every treatment is subject to toxicity issues or to the onset of resistance. It is
therefore important to ensure a particular waiting time for every drug (Assumption 2.1).
In addition, the schedule of treatments are applied by cycles; a cyclicm is a sequence
of drugs defined by,
{(σ1m, h1m), (σ2m, h2m), . . . , (σqm, hqm)}
∞
m=1, (5.7)
such that σim ∈ Σ is the i
th drug applied in cyclic m and him is the waiting time
for drug σim, such that Lσim ≤ him ≤ Uσim , and ∪
q
i=1σim = Σ for each m. The
waiting times are design such that the treatment regimen shrinks the live cancer cell
population over time, while limiting the toxicity to normal cells or avoiding the onset
of drug resistance.
5.2.1. Numerical results
Drug treatment for Triple Negative breast cancer cell line belong to the set Σ =
{Trametinib+ BEZ235, BEZ235, T rametinib} (see Remark (5.2)), the cell phe-
notype measurements were recorded every 12 hours over a 72-hour horizon, and the
dynamics matrix was estimated from the data for n = 2 phenotypic states [7].
The dynamic matrices, Aσ , for the live cancer system are given by,
AP =
[
0.755 0.081
0.169 0.843
]
, AB =
[
0.896 0
0.186 1.083
]
, AT =
[
1.030 0.231
0.022 0.821
]
,
where drug P is Trametinib + BEZ235, drug B is BEZ235, and drug T is
Trametinib. The initial condition, x0 := [220; 612]
T , is the estimated number of
live cells in each phenotypic state at time zero averaged over fifteen samples (see [2]).
The waiting times of Assumption 2.1 are given by Li := 2 (1 day) for all i ∈ Σ,
UP := 4 (2 days), UB := 8 (4 days), and UT := 6 (3 days).
Remark 5.2. Drug Trametinib+BEZ235 can shrink the live cancer cell population
but is highly toxic to normal cells, and is related with the stable sub-system, AP ;
drugsBEZ235 and Trametinib are less toxic to normal cells but can only reduce the
growth rate of live cancel population, and are related with the unstable sub-systems,
AB and AT , respectively.
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The cyclic optimal schedule of the proposed SwMPC is given by,
{(P, 4), (T, 2), (B, 2)}∞m=1, (5.8)
which means that for every cyclicm, drug P is applied 4 consecutive times, then drug
T is applied 2 consecutive times followed by drug P applied 2 consecutive times as
well.
Remark 5.3. Cyclic (5.8) is a trivial solution to stabilize the switched system, because
according to Eq. (5.8) the unique stable sub-system, AP , is applied to the switched
system (2.1) its maximum waiting time (saturating the application of this drug), and
the unstable sub-systems, AT and AB , are applied, by restrictions, just their minimum
waiting times (in order to return the employment of the stable sub-system).
In what follows, we penalize by cost the consecutive use of each treatment instead
of the constraint of maximum waiting time Uσ. Consider the following modified cost
function
J¯N (x;σ) := JN (x;σ) +
N−1∑
j=0
bσ(j)h
σ(j)(j), (5.9)
where JN (x;σ) is given by Eq. (4.1), bσ is a positive weight that penalize the consec-
utive use of treatment σ, and,
hσ(j)(j) =| P [σ, j] |2
is the square cardinal of the j-pack P [σ, j], which accounts all switching signals
consecutively identical to the prediction signal σ(j), therefore term hσ(·) penalizes
the consecutive use of signal σ.
The simulations will be performed with the same conditions presented before, but
regardless of the cycles and the maximum waiting times Uσ of Assumption 2.1, in
order to extend the constraints of the optimization problem and therefore analyze a less
limited result. Illustratively, we will consider three different cases based on the concept
that there are some drugs that are very toxic to healthy cells and other drugs that are
less toxic to healthy cells.
Case 1. bP = bT = bB . The consecutive use of every treatment is equally
penalized by the cost (5.9).
Case 2. bP > bT = bB . The consecutive use of drugP is slightly more penalized
than the consecutive use of drugs T or B.
Case 3. bP >> bT > bB. The consecutive use of drug P is a sight more
penalized than the consecutive use of drug T , and this last one is slightly more
penalized than the consecutive use of drug B.
The first case is shown in Figure 6. The hypothetical Case 1, considers that each
treatment has the same “toxicity level”, therefore the optimal schedule (at the begin-
ning) is the application of the most effective treatment, P . Although each drug is
equally penalized, cost (5.9) also penalizes the consecutive use of any of them, so after
8 times applied treatment P , there is a switch to drug B, which is applied the mini-
mum waiting time, LB = 2, finally returning to drug P . Figure 7 shows the result for
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Figure 6: Phenotype cell measurement and proposed treatment for Case 1.
Case 2. The simulation represents a similar scenario to the first case, nevertheless, the
slightly greater weight bP results in a less number of consecutive times that treatment
P is applied to the system than in Case 1. Figure 8 represents simulations for the third
case showing a complete different scenario; the population of phenotype cells decays
slower than the first cases because the consecutive use of the most effective treatments
are highly penalized.
Remark 5.4. Generally, waiting time constraints related to toxicity or to the onset
of resistance (regardless the application) are satisfied by restrictions, incorporating
computational complexity to the optimization problem, and making them some times a
difficult, if not impossible, task. We have shown in the last simulations that the waiting
times can be cornered by minimizing a particular function cost instead of adding hard
constraints to the problem, which is understood -by the control point of view- as a
benefit in the implementation of the optimization problem.
6. Conclusions
This paper proposed a proper set-based MPC for discrete-time switched system.
The formulation drives the controlled states to a given region of the sate space, which is
defined as an invariant set for the switched system. The proposal was applied to a sim-
plified viral mutation model, proving that it attenuates the effect of the viral mutation
in several scenarios containing the chronic and acute infection cases. The strategy was
compared with some basic viral mutation treatments and the optimal solution showing
that the adverse effects of virus mutation in acute and chronic infection are minimized.
The proposal was applied to schedule an optimal solution for cancer treatment as well.
The possibility of satisfying the maximum waiting times between drugs inputs related
to toxicity or the onset of resistance for some drugs by minimizing a particular func-
tion cost was analyzed. The results showed that the proposal fulfilled different waiting
times for each drug by considering different weights that penalized the consecutive use
of each treatment.
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Figure 7: Phenotype cell measurement and proposed treatment for Case 2.
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Figure 8: Phenotype cell measurement and proposed treatment for Case 3.
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